<p>随着全球市场在利率预期和人工智能驱动的乐观情绪中航行，亚洲经济体凭借其独特的增长叙事吸引了关注。在这种环境下，拥有高内部持股的公司尤其引人注目，因为它们通常反映出与企业最亲近的人士的强烈信心。</p>
<h3>亚洲高内部持股的十大成长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>铜冠黄金集团 (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>苏州三门科技 (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>思能电气 (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>视源科技 (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>诺瑞 (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>老铺黄金 (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>金回路电子 (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>安科生物集团国际 (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>四月生物 (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们高内部持股快速成长亚洲公司的 618 只股票的完整列表。</p>
<p>让我们深入探讨一些筛选出的优质选择。</p>
<h2>康方生物 (SEHK:9926)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 康方生物是一家生物制药公司，专注于全球抗体药物的研究、开发、生产和商业化，市值为 1206.7 亿港元。</p>
<p><strong>运营：</strong> 该公司通过其生物制药产品的研究、开发、生产和销售活动产生了 25.1 亿人民币的收入。</p>
<p><strong>内部持股：</strong> 18.1%</p>
<p><strong>收入增长预测：</strong> 每年 34.4%。</p>
<p>康方生物的增长轨迹得益于其高内部持股和强大的研发管道，专注于创新癌症疗法。公司预测年收入增长 34.4%，超过香港市场。最近的进展包括针对肝细胞癌的 cadonilimab 全球二期临床试验和肺癌研究的良好数据。尽管 2025 年上半年出现净亏损，康方生物对双特异性抗体如 ivonescimab 的战略关注使其在满足全球未满足的医疗需求方面处于良好位置。</p>
<ul>
<li>点击这里访问我们的完整增长分析报告，以了解康方生物的动态。</li>
<li>根据我们的估值报告，康方生物的股价可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SEHK:9926 持股结构</p>
<h2>深圳拓邦 (SZSE:002139)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 深圳拓邦股份有限公司从事智能控制系统解决方案的研究、开发、生产和销售，市值为 199.8 亿人民币。</p>
<p><strong>运营：</strong> 该公司在智能控制电子行业产生了 109.9 亿人民币的收入。</p>
<p><strong>内部持股：</strong> 23.8%</p>
<p><strong>收入增长预测：</strong> 每年 15.6%。</p>
<p>深圳拓邦的增长特点是战略性全球扩张和高内部持股。公司预测年收入增长 15.6%，略高于中国市场平均水平。尽管 2025 年上半年净收入有所下降，但其收益预计将显著增长，年增长率为 27%。墨西哥工厂通过先进的生产线和认证提升了其全球制造效率，支持其智能控制器在多种应用中的表现，同时保持 32.6 倍的市盈率的竞争价值。</p>
<ul>
<li>点击探索我们在深圳拓邦收益增长报告中的详细发现。</li>
<li>我们的综合估值报告提出，深圳拓邦的定价可能低于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SZSE:002139 持股结构</p>
<h2>乐普医疗 (北京) (SZSE:300003)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 乐普医疗（北京）股份有限公司在医疗设备和制药领域运营，市值为 349 亿人民币。</p>
<p><strong>运营：</strong> 乐普医疗（北京）股份有限公司通过其在医疗设备和制药领域的运营产生收入。</p>
<p><strong>内部持股：</strong> 13.1%</p>
<p><strong>收入增长预测：</strong> 每年 14.1%。</p>
<p>乐普医疗（北京）展现出增长潜力，预计收益年增长率为 40%，超过中国市场。尽管最近利润率下降至 4% 且股价波动较大，但其收入预计将以 14.1% 的速度增长，略高于市场平均水平。公司最近批准了对其章程的修订，并为 2025 年每 10 股派发 1.63 元的中期现金红利，反映出积极的股东参与。</p>
<ul>
<li>解锁我们对乐普医疗（北京）股票分析的全面见解，详见此增长报告。</li>
<li>我们编制的估值报告表明，乐普医疗（北京）的当前价格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SZSE:300003 收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>在这里探索我们高内部持股快速成长亚洲公司的 618 个名字。</li>
<li>对其他可能性感兴趣？发现下一个大机会，寻找财务稳健的平价股票，以平衡风险和回报。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

乐普医疗

康方生物

拓邦股份

<p>三家拥有显著内部持股的亚洲成长公司因其预期的收入增长而受到关注：康方生物（SEHK:9926）预计年增长率为 34.4%，得益于其创新的癌症疗法；深圳拓邦股份（SZSE:002139）预计增长 15.6%，受到全球扩张的支持；乐普医疗科技（SZSE:300003）预计增长 14.1%，尽管近期利润率有所下降。这些公司反映了内部人士的强烈信心，并有望在各自的市场中表现优于大盘，尽管有些公司的估值可能高于基于财务数据的合理水平</p>

<p>As global markets navigate the complexities of interest rate expectations and AI-driven optimism, Asian economies are capturing attention with their unique growth narratives. In this environment, companies with high insider ownership can be particularly intriguing as they often reflect strong confidence from those closest to the business.</p>
<div class="lb-trans"><p>随着全球市场在利率预期和人工智能驱动的乐观情绪中航行，亚洲经济体凭借其独特的增长叙事吸引了关注。在这种环境下，拥有高内部持股的公司尤其引人注目，因为它们通常反映出与企业最亲近的人士的强烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亚洲高内部持股的十大成长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Tongguan Gold Group (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>铜冠黄金集团 (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>苏州三门科技 (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>思能电气 (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>视源科技 (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>诺瑞 (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>老铺黄金 (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>金回路电子 (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>安科生物集团国际 (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>四月生物 (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 618 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们高内部持股快速成长亚洲公司的 618 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>让我们深入探讨一些筛选出的优质选择。</p>
</div><h2>Akeso (SEHK:9926)</h2>
<div class="lb-trans"><h2>康方生物 (SEHK:9926)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Akeso, Inc. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of HK$120.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 康方生物是一家生物制药公司，专注于全球抗体药物的研究、开发、生产和商业化，市值为 1206.7 亿港元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥2.51 billion from its activities in the research, development, production, and sale of biopharmaceutical products.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其生物制药产品的研究、开发、生产和销售活动产生了 25.1 亿人民币的收入。</p>
</div><p><strong>Insider Ownership:</strong> 18.1%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 18.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 34.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 34.4%。</p>
</div><p>Akeso's growth trajectory is underscored by its high insider ownership and robust R&amp;D pipeline, focusing on innovative cancer therapies. The company forecasts revenue growth of 34.4% annually, outpacing the Hong Kong market. Recent advancements include the global Phase II trial of cadonilimab for hepatocellular carcinoma and promising data from lung cancer studies. Despite a net loss in H1 2025, Akeso's strategic focus on bispecific antibodies like ivonescimab positions it well in addressing unmet medical needs globally.</p>
<div class="lb-trans"><p>康方生物的增长轨迹得益于其高内部持股和强大的研发管道，专注于创新癌症疗法。公司预测年收入增长 34.4%，超过香港市场。最近的进展包括针对肝细胞癌的 cadonilimab 全球二期临床试验和肺癌研究的良好数据。尽管 2025 年上半年出现净亏损，康方生物对双特异性抗体如 ivonescimab 的战略关注使其在满足全球未满足的医疗需求方面处于良好位置。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Akeso.</li>
<li>According our valuation report, there's an indication that Akeso's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整增长分析报告，以了解康方生物的动态。</li>
<li>根据我们的估值报告，康方生物的股价可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown"/></p>
<p>SEHK:9926 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SEHK:9926 持股结构</p>
</div><h2>Shenzhen Topband (SZSE:002139)</h2>
<div class="lb-trans"><h2>深圳拓邦 (SZSE:002139)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shenzhen Topband Co., Ltd. is involved in the research, development, production, and sale of intelligent control system solutions both in China and internationally, with a market cap of CN¥19.98 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳拓邦股份有限公司从事智能控制系统解决方案的研究、开发、生产和销售，市值为 199.8 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥10.99 billion from its Intelligent Control Electronics Industry segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司在智能控制电子行业产生了 109.9 亿人民币的收入。</p>
</div><p><strong>Insider Ownership:</strong> 23.8%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 23.8%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 15.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 15.6%。</p>
</div><p>Shenzhen Topband's growth is marked by strategic global expansion and high insider ownership. The company forecasts revenue growth of 15.6% annually, slightly above the Chinese market average. Its earnings are expected to grow significantly at 27% per year, despite a recent dip in net income for H1 2025. The Mexico facility enhances its global manufacturing efficiency with advanced production lines and certifications, supporting its smart controller segment across diverse applications while maintaining competitive value with a P/E ratio of 32.6x.</p>
<div class="lb-trans"><p>深圳拓邦的增长特点是战略性全球扩张和高内部持股。公司预测年收入增长 15.6%，略高于中国市场平均水平。尽管 2025 年上半年净收入有所下降，但其收益预计将显著增长，年增长率为 27%。墨西哥工厂通过先进的生产线和认证提升了其全球制造效率，支持其智能控制器在多种应用中的表现，同时保持 32.6 倍的市盈率的竞争价值。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Shenzhen Topband's earnings growth report.</li>
<li>Our comprehensive valuation report raises the possibility that Shenzhen Topband is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在深圳拓邦收益增长报告中的详细发现。</li>
<li>我们的综合估值报告提出，深圳拓邦的定价可能低于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown"/></p>
<p>SZSE:002139 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:002139 持股结构</p>
</div><h2>Lepu Medical Technology (Beijing) (SZSE:300003)</h2>
<div class="lb-trans"><h2>乐普医疗 (北京) (SZSE:300003)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Lepu Medical Technology (Beijing) Co., Ltd. operates in the medical device and pharmaceutical sectors, with a market cap of CN¥34.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 乐普医疗（北京）股份有限公司在医疗设备和制药领域运营，市值为 349 亿人民币。</p>
</div><p><strong>Operations:</strong> Lepu Medical Technology (Beijing) Co., Ltd. generates revenue from its operations in the medical device and pharmaceutical sectors.</p>
<div class="lb-trans"><p><strong>运营：</strong> 乐普医疗（北京）股份有限公司通过其在医疗设备和制药领域的运营产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 13.1%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 13.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 14.1% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 14.1%。</p>
</div><p>Lepu Medical Technology (Beijing) demonstrates growth potential with forecasted earnings growth of 40% annually, outpacing the Chinese market. Despite a recent decline in profit margins to 4% and high share price volatility, its revenue is expected to grow at 14.1%, slightly above the market average. The company recently approved amendments to its articles of association and an interim cash dividend of CNY 1.63 per 10 shares for 2025, reflecting active shareholder engagement.</p>
<div class="lb-trans"><p>乐普医疗（北京）展现出增长潜力，预计收益年增长率为 40%，超过中国市场。尽管最近利润率下降至 4% 且股价波动较大，但其收入预计将以 14.1% 的速度增长，略高于市场平均水平。公司最近批准了对其章程的修订，并为 2025 年每 10 股派发 1.63 元的中期现金红利，反映出积极的股东参与。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Lepu Medical Technology (Beijing) stock in this growth report.</li>
<li>The valuation report we've compiled suggests that Lepu Medical Technology (Beijing)'s current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对乐普医疗（北京）股票分析的全面见解，详见此增长报告。</li>
<li>我们编制的估值报告表明，乐普医疗（北京）的当前价格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300003 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:300003 收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Explore the 618 names from our Fast Growing Asian Companies With High Insider Ownership screener here.</li>
<li>Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们高内部持股快速成长亚洲公司的 618 个名字。</li>
<li>对其他可能性感兴趣？发现下一个大机会，寻找财务稳健的平价股票，以平衡风险和回报。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

3 家亚洲增长型公司，内部人士持股，预计收入增长可达 34%